Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- 16 May 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 395 (10236), 1547-1557
- https://doi.org/10.1016/S0140-6736(20)30230-0
Abstract
No abstract availableFunding Information
- F. Hoffmann-La Roche
- National Health and Medical Research Council (APP1102604)
- Genentech
This publication has 26 references indexed in Scilit:
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2017
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerJournal of Clinical Oncology, 2016
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- Molecular Pathways: The Immunogenic Effects of Platinum-Based ChemotherapeuticsClinical Cancer Research, 2014
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinomaAnnals of Oncology, 2011
- A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapyThe Lancet Oncology, 2011
- First-Line Systemic Therapy Trials for Advanced Transitional-Cell Carcinoma of the Urothelium: Should We Stop Separating Cisplatin-Eligible and -Ineligible Patients?Journal of Clinical Oncology, 2010
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005